艾伯維藥品ABBV
紐約證券 · USD
248.67
-0.11
(-0.04%)
盤中 09/10 01:12 (UTC+8)
09/10 01:12 (UTC+8)
艾伯維藥品ABBV
248.67
-0.11
(-0.04%)
財務數據
損益表
- 123.10
- 144.62
- 144.60
- 151.02
- 133.43
- 154.23
- 157.76
- 166.18
- 150.02
- 169.90
- -13.92
- 17.48
- -0.01
- 4.44
- -11.65
- 15.59
- 2.29
- 5.34
- -9.72
- 13.25
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2026/Q2 | 2026/Q1 | 2025/Q4 | 2025/Q3 | 2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | |
營業收入淨額 | 16,990,000 | 15,002,000 | 16,618,000 | 15,776,000 | 15,423,000 | 13,343,000 | 15,102,000 | 14,460,000 | 14,462,000 | 12,310,000 |
營業成本 | 4,291,000 | 4,218,000 | 4,552,000 | 5,304,000 | 4,346,000 | 4,002,000 | 4,396,000 | 4,212,000 | 4,202,000 | 4,094,000 |
營業毛利 | 12,699,000 | 10,784,000 | 12,066,000 | 10,472,000 | 11,077,000 | 9,341,000 | 10,706,000 | 10,248,000 | 10,260,000 | 8,216,000 |
營業費用 | 6,267,000 | 6,794,000 | 7,522,000 | 8,568,000 | 6,183,000 | - | - | 6,417,000 | 6,262,000 | - |
研發費用 | 2,344,000 | 2,472,000 | 2,579,000 | 2,319,000 | 2,131,000 | 2,067,000 | 6,774,000 | 2,130,000 | 1,948,000 | 1,939,000 |
推銷及管理費用 | 3,632,000 | 3,578,000 | 3,678,000 | 3,569,000 | 3,229,000 | 3,293,000 | 3,848,000 | 4,205,000 | 3,377,000 | 3,315,000 |
非經常性項目費用 | 291,000 | 744,000 | 1,265,000 | 2,680,000 | 823,000 | 248,000 | 1,574,000 | 82,000 | 937,000 | 164,000 |
其他營業費用 | - | - | - | - | - | - | - | - | - | - |
營業利益 | 6,432,000 | 3,990,000 | 4,544,000 | 1,904,000 | 4,894,000 | 3,733,000 | -1,490,000 | 3,831,000 | 3,998,000 | 2,798,000 |
其他收入及費用 | -1,475,000 | -2,306,000 | -1,221,000 | -523,000 | -2,662,000 | -1,445,000 | -169,000 | -1,156,000 | -1,346,000 | -590,000 |
利息費用 | 679,000 | 645,000 | 655,000 | 667,000 | 678,000 | 627,000 | 610,000 | 591,000 | 506,000 | 453,000 |
稅前純益 | 4,278,000 | 1,039,000 | 2,668,000 | 714,000 | 1,554,000 | 1,661,000 | -2,269,000 | 2,084,000 | 2,146,000 | 1,755,000 |
所得稅 | 662,000 | 342,000 | 853,000 | 526,000 | 613,000 | 372,000 | -2,246,000 | 520,000 | 773,000 | 383,000 |
稅後純益 | 3,613,000 | 695,000 | 1,816,000 | 186,000 | 938,000 | 1,286,000 | -22,000 | 1,561,000 | 1,370,000 | 1,369,000 |
基本每股稅後盈餘(元) | 2.04 | 0.39 | 1.03 | 0.10 | 0.52 | 0.73 | -0.01 | 0.88 | 0.77 | 0.77 |
稀釋每股稅後盈餘(元) | 2.03 | 0.39 | 1.02 | 0.10 | 0.52 | 0.72 | -0.02 | 0.88 | 0.76 | 0.77 |
基本平均股數(千股) | 1767069.00 | 1770000.00 | 1767384.00 | 1769000.00 | 1768000.00 | 1766288.00 | 1765256.00 | 1767104.00 | 1765942.00 | 1769000.00 |
稀釋平均股數(千股) | 1771000.00 | 1774000.00 | 1774000.00 | 1772000.00 | 1771000.00 | 1772000.00 | 1769000.00 | 1772000.00 | 1771000.00 | 1773000.00 |
還原基本每股稅後盈餘(元) | 2.04 | 0.39 | 1.03 | 0.10 | 0.52 | 0.73 | -0.01 | 0.88 | 0.77 | 0.77 |
還原稀釋每股稅後盈餘(元) | 2.03 | 0.39 | 1.02 | 0.10 | 0.52 | 0.72 | -0.02 | 0.88 | 0.76 | 0.77 |
還原基本平均股數(千股) | 1,767,069 | 1,770,000 | 1,767,384 | 1,769,000 | 1,768,000 | 1,766,288 | 1,765,256 | 1,767,104 | 1,765,942 | 1,769,000 |
還原稀釋平均股數(千股) | 1,771,000 | 1,774,000 | 1,774,000 | 1,772,000 | 1,771,000 | 1,772,000 | 1,769,000 | 1,772,000 | 1,771,000 | 1,773,000 |
EBITDA(千元) | 6,837,000 | 3,618,000 | 5,311,000 | 3,442,000 | 4,279,000 | 4,324,000 | 444,000 | 4,751,000 | 4,780,000 | 4,279,000 |